HRP20000771A2 - COMBINATIONS OF PROTEIN FARNESYLTRANSFERASE AND HMG CoA REDUCTASE INHIBITORS AND THEIR USE TO TREAT CANCER - Google Patents
COMBINATIONS OF PROTEIN FARNESYLTRANSFERASE AND HMG CoA REDUCTASE INHIBITORS AND THEIR USE TO TREAT CANCER Download PDFInfo
- Publication number
- HRP20000771A2 HRP20000771A2 HR20000771A HRP20000771A HRP20000771A2 HR P20000771 A2 HRP20000771 A2 HR P20000771A2 HR 20000771 A HR20000771 A HR 20000771A HR P20000771 A HRP20000771 A HR P20000771A HR P20000771 A2 HRP20000771 A2 HR P20000771A2
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- phenyl
- carbamoyl
- ethyl
- imidazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8520298P | 1998-05-12 | 1998-05-12 | |
| US9225398P | 1998-07-10 | 1998-07-10 | |
| PCT/US1999/010188 WO1999058505A2 (en) | 1998-05-12 | 1999-05-10 | Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20000771A2 true HRP20000771A2 (en) | 2001-06-30 |
Family
ID=26772425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20000771A HRP20000771A2 (en) | 1998-05-12 | 1999-05-10 | COMBINATIONS OF PROTEIN FARNESYLTRANSFERASE AND HMG CoA REDUCTASE INHIBITORS AND THEIR USE TO TREAT CANCER |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6492410B1 (is) |
| EP (1) | EP1077949A2 (is) |
| JP (1) | JP2002514628A (is) |
| KR (1) | KR20010043529A (is) |
| CN (1) | CN1171874C (is) |
| AP (1) | AP2000001984A0 (is) |
| AU (1) | AU758891B2 (is) |
| BG (1) | BG105003A (is) |
| BR (1) | BR9911785A (is) |
| CA (1) | CA2331295A1 (is) |
| EA (1) | EA003860B1 (is) |
| EE (1) | EE200000660A (is) |
| GE (1) | GEP20032996B (is) |
| HR (1) | HRP20000771A2 (is) |
| HU (1) | HUP0102322A3 (is) |
| ID (1) | ID27933A (is) |
| IL (1) | IL139502A0 (is) |
| IS (1) | IS5713A (is) |
| NO (1) | NO20005680L (is) |
| NZ (1) | NZ508357A (is) |
| OA (1) | OA11551A (is) |
| PL (1) | PL344662A1 (is) |
| SK (1) | SK16742000A3 (is) |
| WO (1) | WO1999058505A2 (is) |
| YU (1) | YU68900A (is) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002536405A (ja) * | 1999-02-11 | 2002-10-29 | イーデンランド、インコーポレイテッド | ウイルス感染症の治療方法 |
| US6455734B1 (en) * | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| US20020010128A1 (en) * | 2000-04-13 | 2002-01-24 | Parks Thomas P. | Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism |
| US20020132781A1 (en) * | 2000-10-06 | 2002-09-19 | George Kindness | Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor |
| GB0220885D0 (en) * | 2002-09-09 | 2002-10-16 | Novartis Ag | Organic compounds |
| WO2005042710A1 (en) * | 2003-10-28 | 2005-05-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of statin to kill ebv-transformed b cells |
| SG166829A1 (en) * | 2005-11-08 | 2010-12-29 | Ranbaxy Lab Ltd | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| KR100930365B1 (ko) * | 2006-11-09 | 2009-12-08 | 덕성여자대학교 산학협력단 | 심바스타틴을 유효성분으로 함유하는 유방암 치료용 약학적조성물 |
| US20080119444A1 (en) * | 2006-11-16 | 2008-05-22 | Steven Lehrer | Methods and compositions for the treatment of cancer |
| US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
| US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK523288A (da) * | 1987-10-06 | 1989-04-07 | Hoffmann La Roche | Aminosyrederivater |
| NL9002031A (nl) | 1990-09-14 | 1992-04-01 | Voskuilen Woudenberg Bv | Inrichting voor het bewerken van een uitwendig buisoppervlak. |
| US5571792A (en) | 1994-06-30 | 1996-11-05 | Warner-Lambert Company | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase |
| DE69630120T2 (de) | 1995-06-22 | 2004-04-08 | Biogen, Inc., Cambridge | Kristalle von fragmenten von cd40-liganden und deren verwendung |
| KR19990028303A (ko) * | 1995-06-22 | 1999-04-15 | 한센 핀 베네드, 안네 제헤르 | 성장호르몬 방출 특성을 가지는 화합물 |
| UA57081C2 (uk) | 1997-06-16 | 2003-06-16 | Пфайзер Продактс Інк. | Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування |
-
1999
- 1999-05-10 CA CA002331295A patent/CA2331295A1/en not_active Abandoned
- 1999-05-10 US US09/674,818 patent/US6492410B1/en not_active Expired - Fee Related
- 1999-05-10 CN CNB99807649XA patent/CN1171874C/zh not_active Expired - Fee Related
- 1999-05-10 YU YU68900A patent/YU68900A/sh unknown
- 1999-05-10 AU AU39792/99A patent/AU758891B2/en not_active Ceased
- 1999-05-10 KR KR1020007012632A patent/KR20010043529A/ko not_active Ceased
- 1999-05-10 EP EP99922898A patent/EP1077949A2/en not_active Withdrawn
- 1999-05-10 IL IL13950299A patent/IL139502A0/xx unknown
- 1999-05-10 HR HR20000771A patent/HRP20000771A2/hr not_active Application Discontinuation
- 1999-05-10 GE GEAP19995670A patent/GEP20032996B/en unknown
- 1999-05-10 ID IDW20002583A patent/ID27933A/id unknown
- 1999-05-10 PL PL99344662A patent/PL344662A1/xx not_active Application Discontinuation
- 1999-05-10 SK SK1674-2000A patent/SK16742000A3/sk unknown
- 1999-05-10 EE EEP200000660A patent/EE200000660A/xx unknown
- 1999-05-10 HU HU0102322A patent/HUP0102322A3/hu unknown
- 1999-05-10 BR BR9911785-1A patent/BR9911785A/pt not_active IP Right Cessation
- 1999-05-10 OA OA1200000310A patent/OA11551A/en unknown
- 1999-05-10 WO PCT/US1999/010188 patent/WO1999058505A2/en not_active Ceased
- 1999-05-10 JP JP2000548309A patent/JP2002514628A/ja active Pending
- 1999-05-10 AP APAP/P/2000/001984A patent/AP2000001984A0/en unknown
- 1999-05-10 EA EA200001164A patent/EA003860B1/ru not_active IP Right Cessation
- 1999-05-10 NZ NZ508357A patent/NZ508357A/xx unknown
-
2000
- 2000-11-10 IS IS5713A patent/IS5713A/is unknown
- 2000-11-10 NO NO20005680A patent/NO20005680L/no not_active Application Discontinuation
- 2000-11-29 BG BG105003A patent/BG105003A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1077949A2 (en) | 2001-02-28 |
| AU3979299A (en) | 1999-11-29 |
| CA2331295A1 (en) | 1999-11-18 |
| CN1171874C (zh) | 2004-10-20 |
| HUP0102322A2 (hu) | 2001-11-28 |
| WO1999058505A2 (en) | 1999-11-18 |
| AP2000001984A0 (en) | 2000-12-31 |
| JP2002514628A (ja) | 2002-05-21 |
| NZ508357A (en) | 2002-09-27 |
| WO1999058505A3 (en) | 2000-01-06 |
| YU68900A (sh) | 2002-12-10 |
| EE200000660A (et) | 2002-04-15 |
| BR9911785A (pt) | 2001-04-03 |
| NO20005680L (no) | 2001-01-10 |
| PL344662A1 (en) | 2001-11-19 |
| BG105003A (en) | 2001-07-31 |
| IL139502A0 (en) | 2001-11-25 |
| HUP0102322A3 (en) | 2001-12-28 |
| EA003860B1 (ru) | 2003-10-30 |
| AU758891B2 (en) | 2003-04-03 |
| KR20010043529A (ko) | 2001-05-25 |
| GEP20032996B (en) | 2003-06-25 |
| OA11551A (en) | 2004-05-24 |
| HK1038355A1 (en) | 2002-03-15 |
| CN1306515A (zh) | 2001-08-01 |
| US6492410B1 (en) | 2002-12-10 |
| EA200001164A1 (ru) | 2001-06-25 |
| SK16742000A3 (sk) | 2001-07-10 |
| NO20005680D0 (no) | 2000-11-10 |
| ID27933A (id) | 2001-05-03 |
| IS5713A (is) | 2000-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5840918A (en) | Isoprenyl transferase inhibitors | |
| BG102936A (bg) | Инхибитори на протеин фарнезил трансфераза | |
| ES2214021T3 (es) | Derivados funcionalizados de glicinamidas con cadena lateral de alquilo y alquenilo como inhibidores de la farnesil-transferasa. | |
| US9708255B2 (en) | (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders | |
| KR100430207B1 (ko) | 효소억제제 | |
| US6300501B1 (en) | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase | |
| FR2518088A1 (fr) | Nouveaux derives d'aminoacides, et leur application therapeutique | |
| EP0696593A2 (en) | Inhibitors of farnesyl protein transferase | |
| HUP0401253A2 (hu) | Dolastatin 10 származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HRP20000771A2 (en) | COMBINATIONS OF PROTEIN FARNESYLTRANSFERASE AND HMG CoA REDUCTASE INHIBITORS AND THEIR USE TO TREAT CANCER | |
| JPH11501288A (ja) | 金属タンパク質分解酵素阻害剤 | |
| HRP970693A2 (en) | Cycloalkyl inhibitors of protein farnesyltransferase | |
| MXPA00011113A (en) | Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer | |
| CZ20004073A3 (cs) | Kombinace proteinové farnesyl transferázy a inhibitorů HMG CoA reduktázy a jejich použití při léčbě rakoviny | |
| ZA200006491B (en) | Combinations of protein farnesyltransferase and HMG CoA reductase inhibitors and their use to treat cancer. | |
| RU2675237C1 (ru) | Соединение (6-{ [(1S)-1(5-фтор-4-оксо-3-фенил-3,4-дигидрохиназолин-2-ил)пропил]амино} -9Н-пурин-9-ил)метилацетат как ингибитор p110δ - дельта-изоформы фосфоинозитид-3-киназы (PI3K), способы его получения (варианты) и применения | |
| PL190637B1 (pl) | Terapeutycznie aktywne estry i tioestry, kompozycje farmaceutyczne i zastosowanie estrów i tioestrów | |
| HUP9903221A2 (hu) | A protein farneliz transzferáz enzimet gátló vegyületek | |
| MXPA00009613A (en) | Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors | |
| MXPA99001592A (es) | Inhibidores cicloalquilo de proteina farnesiltransferasa | |
| KR20000015892A (ko) | 단백질 파르네실 트랜스퍼라제의 억제제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODBI | Application refused |